Thursday, July 3, 2025 7/3/2025

Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy

Award Number: R01CA247941
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/15/2021
PERIOD OF PERFORMANCE END DATE: 01/31/2026

Group Awards By:

View Award Description

Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy - Summary: The exquisite specificity, amplitude, and quality of T cells govern tumor initiation, progression, and responses to therapy. Two of the most revolutionary and promising immunotherapies are the immune checkpoint blockade and the adoptive cell transfer, which are both dependent on the robust engagement of cytotoxic T effector (Teff) cells to control or eradicate cancer. A robust T cell-mediated anti-tumor response requires the coordination of nutrient and energy supplies with Teff cell expansion and function. However, the high metabolic demands of tumor cells compromise the function of Teff cells by competing for nutrients within the tumor micro-environment (TME). We propose that the critical barrier, which limits the patient’s response to immunotherapy, is the hostile metabolic microenvironment within tumors. We have previously shown that the transcription factors c-Myc and HIF1alpha are differentially required for driving the central carbon metabolic programs during T cell acti-vation and differentiation. We recently revealed that asparagine (Asn) is the most upregulated amino acid upon T cell activation, and its bioavailability represents a key metabolic node that governs the central carbon metab-olism and effector function in Teff cells. Some cancer cells solely rely on extracellular Asn to support growth and proliferation, representing a metabolic vulnerability of cancer. However, Teff cells can maintain an intracellular Asn pool for cell growth and function either through the uptake of extracellular Asn or through de novo biosyn-thesis of Asn, indicating a layer of metabolic plasticity of T cells. Enforced restriction of extracellular Asn rewires central carbon catabolic programs, leading to enhanced anti-tumor effector function in Teff cells. Moreover, these Teff cells are characterized by an enhanced ATF4 and Nrf2 signaling response. Hence, we hypothesize that modulation of Asn bioavailability can optimize carbon assimilation and integrate stress-response sig-naling pathways, enabling a robust anti-tumor response in metabolically restricted tumor microenviron-ments. To test our hypothesis, we propose to 1) decipher the reprogramming of central carbon metabolic path-ways and assess the impact of key metabolic steps on Teff cells in the context of Asn restriction; 2) determine the role of ATF4/Nrf2 axis in regulating the effector function of Teff cells; 3) target critical signaling and metabolic nodes to engineer central carbon catabolic programs, thus enhancing function and persistence of Teff cells, and 4) develop and test strategies to simultaneously exploit Asn dependence as a cancer cell metabolic vulnerability and maximize systemic anti-tumor immunity. Collectively, the completion of this project will reveal fundamental principles of the emerging connections between the tumor’s microenvironment, cell metabolism, and anti-tumor immunity. These studies are critical to developing novel approaches that improve clinical outcomes of cancer immunotherapy substantially.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $479,843 )
2025	2025	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	002	5	6/6/2025	NON-COMPETING CONTINUATION	$47,984
2025	2025	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	001	5	2/14/2025	NON-COMPETING CONTINUATION	$0
2025	2025	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	000	5	1/20/2025	NON-COMPETING CONTINUATION	$431,859
														Subtotal = $479,843

Issue Date FY: 2024 ( Subtotal = $455,851 )
2024	2024	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	001	4	4/18/2024	NON-COMPETING CONTINUATION	$23,992
2024	2024	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	000	4	1/29/2024	NON-COMPETING CONTINUATION	$431,859
														Subtotal = $455,851

Issue Date FY: 2023 ( Subtotal = $470,246 )
2023	2023	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	000	3	2/1/2023	NON-COMPETING CONTINUATION	$470,246
														Subtotal = $470,246

Issue Date FY: 2022 ( Subtotal = $470,246 )
2022	2022	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	000	2	1/13/2022	NON-COMPETING CONTINUATION	$431,858
2022	2022	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	001	2	5/24/2022	NON-COMPETING CONTINUATION	$38,388
														Subtotal = $470,246

Issue Date FY: 2021 ( Subtotal = $506,843 )
2021	2021	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Cancer Biology Research	000	1	2/15/2021	NEW	$506,843
														Subtotal = $506,843

Grand Total All Awards = $2,383,029

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy

Award Number: R01CA247941

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/15/2021

PERIOD OF PERFORMANCE END DATE: 01/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer